Huadong Medicine Co Ltd
SZSE:000963
Intrinsic Value
Huadong Medicine Co., Ltd. engages in the production and sale of antibiotics, proprietary Chinese medicine, chemical synthetic medicine, and genetic engineering drugs. [ Read More ]
The intrinsic value of one
Huadong Medicine Co Ltd
stock under the Base Case scenario is
56.8
CNY.
Compared to the current market price of 31.55 CNY,
Huadong Medicine Co Ltd
is
Undervalued by 44%.
Huadong Medicine Co Ltd's market capitalization is 55.2B CNY.
Huadong Medicine Co Ltd stock price is 31.55 CNY.
Huadong Medicine Co Ltd stock price (31.55 CNY) is 44% less than its Intrinsic Value (56.8 CNY).
Huadong Medicine Co Ltd stock price (31.55 CNY) is 41% less than its DCF Value (53.04 CNY). Open DCF Valuation
Huadong Medicine Co Ltd stock price (31.55 CNY) is 48% less than its Relative Value (60.56 CNY). Open Relative Valuation
Huadong Medicine Co Ltd has upside potential of 66% compared to the average analyst price target.
Open Wall St Estimates
Huadong Medicine Co Ltd has positive Operating Income for the last twelve months.
Huadong Medicine Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 13%.
Huadong Medicine Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 14% to 13%.
Huadong Medicine Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 17% to 14%.
Huadong Medicine Co Ltd's Revenue has grown by 10% over the past 12 months.
Huadong Medicine Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 14%.
Huadong Medicine Co Ltd has positive Net Income for the last twelve months.
Huadong Medicine Co Ltd has positive three-year average ROIC (Return on Invested Capital): 13%. The company is efficient at using invested capital to generate operating income.
Huadong Medicine Co Ltd's Revenue has been growing by 7% per year for the last 3 years.
Huadong Medicine Co Ltd's Revenue is forecast to grow at a rate of 11% per year over the next 3 years.
Huadong Medicine Co Ltd has positive Free Cash Flow for the last twelve months.
Huadong Medicine Co Ltd has positive three-year average ROE (Return on Equity): 16%. The company is efficient at transforming stockholders' equity into net income.
Huadong Medicine Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (4B CNY) than debt (4B CNY).
Huadong Medicine Co Ltd's short-term assets (20B CNY) exceed its short-term liabilties (12B CNY).
Huadong Medicine Co Ltd has positive Gross Profit for the last twelve months.
Huadong Medicine Co Ltd's long-term assets (34B CNY) exceed its long-term liabilties (14B CNY).
Huadong Medicine Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.18.
Huadong Medicine Co Ltd's Altman Z-Score is very high and is equal to 5.69.
Valuation Backtest
Huadong Medicine Co Ltd
Run backtest to discover the historical profit from buying and selling
Huadong Medicine Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Huadong Medicine Co Ltd
Balance Sheet Decomposition
Huadong Medicine Co Ltd
| Current Assets | 19.6B |
| Cash & Short-Term Investments | 4B |
| Receivables | 10.3B |
| Other Current Assets | 5.3B |
| Non-Current Assets | 14.4B |
| Long-Term Investments | 2B |
| PP&E | 5B |
| Intangibles | 5.7B |
| Other Non-Current Assets | 1.7B |
| Current Liabilities | 11.6B |
| Accounts Payable | 5B |
| Accrued Liabilities | 236.5m |
| Short-Term Debt | 2.8B |
| Other Current Liabilities | 3.6B |
| Non-Current Liabilities | 2.1B |
| Long-Term Debt | 834.4m |
| Other Non-Current Liabilities | 1.2B |
Earnings Waterfall
Huadong Medicine Co Ltd
|
Revenue
|
40.3B
CNY
|
|
Cost of Revenue
|
-27.6B
CNY
|
|
Gross Profit
|
12.6B
CNY
|
|
Operating Expenses
|
-8.9B
CNY
|
|
Operating Income
|
3.7B
CNY
|
|
Other Expenses
|
-982.7m
CNY
|
|
Net Income
|
2.7B
CNY
|
Free Cash Flow Analysis
Huadong Medicine Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Huadong Medicine Co Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Huadong Medicine Co Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Huadong Medicine Co Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
Huadong Medicine Co Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Huadong Medicine Co Ltd
According to Wall Street analysts, the average 1-year price target for
Huadong Medicine Co Ltd
is 52.42 CNY
with a low forecast of 41.92 CNY and a high forecast of 65.1 CNY.
Shareholder Return
Price
Huadong Medicine Co Ltd
| Average Annual Return | 16.64% |
| Standard Deviation of Annual Returns | 29.94% |
| Max Drawdown | -50% |
| Market Capitalization | 54.8B CNY |
| Shares Outstanding | 1 754 329 984 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Huadong Medicine Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Huadong Medicine Co., Ltd. engages in the production and sale of antibiotics, proprietary Chinese medicine, chemical synthetic medicine, and genetic engineering drugs. The company is headquartered in Hangzhou, Zhejiang and currently employs 12,427 full-time employees. The company went IPO on 2000-01-27. The firm is mainly engaged in the research and development of pharmaceuticals, the production and sales of chemical drugs, bulk drugs and preparations of traditional Chinese medicine, the distribution and retails of pharmaceuticals, medicine modern logistics, health industry, and the manufacturing and sales of medical beauty products. The firm's products principally include Chinese patent drugs, immunosuppressive agents, endocrine drugs, digestive system drugs, antineoplastic drugs, cardiovascular drugs and antibiotic drugs. The firm distributes its products in domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Huadong Medicine Co Ltd
stock under the Base Case scenario is
56.8
CNY.
Compared to the current market price of 31.55 CNY,
Huadong Medicine Co Ltd
is
Undervalued by 44%.
You don't have any saved screeners yet
